[
  {
    "chunk_id": 0,
    "text": "PRACTICE GUIDELINES 1 NationalInstituteforHealthandCare Excellence, ManchesterM14BD, UK Chronic Kidney disease: summary of updated NICE guidance 2 NHS, Manchester, UK 3 RenalDepartment, StJamess YolandaVMartinez, 1IvanBenett, 2AndrewJPLewington, 3AnthonySWierzbicki4, onbehalfofthe UniversityHospital, Leeds, UK GuidelineCommittee 4 DepartmentofMetabolic Medicine/ChemicalPathology, Guys Whatyouneedtoknow type2diabetes, anACRof≥30mg/mmol, andwho StThomasHospitals, London, UK meetthecriteriainthemarketingauthorisation Theupdatedguidelinedoesnotrecommendadjusting Correspondenceto: YVMartinez (includingrelevanteGFRthresholds) yolanda. martineznice. org. uk theestimationofglomerularfiltrationrate(glomerular filtration rate)in Citethisas: BMJ2021; 374: n1992 peopleofAfrican-CaribbeanorAfricanfamily background Chronickidneydisease(chronic kidney disease)iscommon, estimated toaffect13%ofadults(≥16yearsold)inEngland. 1 Published: 06September2021 Screenpeopleatriskofchronickidneydisease(chronic kidney disease) PeoplewithCKDhaveawiderangeofexperiences, usingestimatedGFR(estimated glomerular filtration rate)andalbumintocreatinine frombeingasymptomaticatearlystagestokidney ratio(albumin-creatinine ratio) failurewithadvanceddisease(seetable1fora Usethefour-variableKidneyFailureRiskEquation classificationofCKDstages). Theprevalenceof insteadofeGFRthresholdforreferral categoriesG3toG5(moreseveredisease)is5%for ReferadultswithCKDandafiveyearriskofneeding alladults, risingto34%inpeopleaged75andover. renalreplacementtherapyof5%(measuredwiththe Askidneydysfunctionadvances, themortalityrisk KidneyFailureRiskEquation)forspecialist increases, asdoesriskofcardiovasculardisease, and assessment somecomorbidities(suchasdiabetesand Offerasodium-glucosecotransporter-2(SGLT2) hypertension)becomemoresevere. Mostadultswith inhibitor, inadditiontoanoptimiseddoseof CKDaremanagedprimarilyinprimarycare, butthey angiotensinconvertingenzyme(ACE)inhibitoror mayneedmoreinputfromsecondarycareasthe angiotensinreceptorblocker(angiotensin receptor blocker), topeoplewith diseaseprogresses. Table1Classificationofchronickidneydisease(chronic kidney disease)inadults, andriskofadverseoutcomesbycategory Albumintocreatinineratio(albumin-creatinine ratio)category Glomerularfiltrationrate(glomerular filtration rate) A1: Normaltomildlyincreased(3 A2: Moderatelyincreased(3-30 A3: Severelyincreased(30 category magnesium/mmol) magnesium/mmol) magnesium/mmol) G1: Normalandhigh(≥90 Lowrisk Moderaterisk Highrisk milliliters per minute/1. 73m2) NoCKDifnoothermarkersofkidney damage G2: Mildreductionrelatedtonormal Lowrisk Moderaterisk Highrisk rangeforayoungadult(60-89 NoCKDiftherearenoothermarkers milliliters per minute/1. 73m2) ofkidneydamage G3a: Mildtomoderatereduction Moderaterisk Highrisk Veryhighrisk (45-59mL/min/1. 73m2) G3b: Moderatetoseverereduction Highrisk Veryhighrisk Veryhighrisk (30-44mL/min/1. 73m2) G4: Severereduction(15-29 Veryhighrisk Veryhighrisk Veryhighrisk milliliters per minute/1. 73m2) G5: Kidneyfailure(15 Veryhighrisk Veryhighrisk Veryhighrisk milliliters per minute/1. 73m2) InAugust2021, theNationalInstituteforHealthand rate(glomerular filtration rate)inpeoplefromblack, Asian, andminority CareExcellence(NICE)publishedNG203, 2anupdated ethnicgroups, andnewcriteriaforriskassessment andcombinedversionofthreeguidelines: chronic andreferraltosecondarycare. 2 kidneydiseaseinadults: assessmentand Recommendations management, chronickidneydisease(stage4or 5): managementofhyperphosphataemia, and NICErecommendationsarebasedonsystematic chronickidneydisease: managinganaemia. The reviewsofbestavailableevidenceandexplicit guidelinewasextendedtocovertheassessmentand considerationofcosteffectiveness. Whenminimal managementofchronickidneydiseaseinchildren evidenceisavailable, recommendationsarebased andyoungpeople. Thisarticlesummarisesthemost ontheGuidelineCommitteesexperienceandopinion recentrecommendationsfromNG203includingnew ofwhatconstitutesgoodpractice. Evidencelevelsfor recommendationsonsodium-glucosecotransporter-2 therecommendationsaregiveninitalicinsquare (SGLT2)inhibitors, estimatingglomerularfiltration brackets. thebmjBMJ2021; 374: n1992 doi: 10. 1136/bmj. n1992 1 PRACTICE Investigationsforchronickidneydiseaseinchildren oftheGFR; andinadultswhousehighproteindietarysupplements (suchasproteinshakes). MostchildrenandyoungpeoplewithCKDwillbemanagedprimarily insecondarycare. However, initialidentificationofCKDmaywell Riskassessment, referralcriteria, andsharedcare occurinprimarycare, andthefollowingriskfactorsshouldprompt ThecommitteelookedatnewevidencefromaUKvalidationstudy3 considerationofinvestigationsforCKDinchildrenandyoung ofthefour-variableKidneyFailureRiskEquationforadults(based people. onage, sex, estimated glomerular filtration rate, andurineACR), whichcanbeusedasacriterion OffertestingforCKDusingeGFRcreatinine(GFRestimatedfrom foridentifyingpeoplewhowillbenefitfromreferraltosecondary serumcreatinine)andalbumintocreatinineratio(albumin-creatinine ratio)to care. Theresultsofboththevalidationstudyandmodelling childrenandyoungpeoplewithanyofthefollowingriskfactors: undertakenfortheguidelineshowedthatusingthisequationas oneofthereferralcriteria(ratherthananeGFRthreshold)waslikely Previousepisodeofacutekidneyinjury tobebothmoresensitiveandmorespecificthanthecriteriainthe 2014NICEguideline, meaningpeoplewhowillprogresstoneeding Solitaryfunctioningkidney. renalreplacementtherapyareidentifiedearlier, andtherearefewer Basedonverylowtohighqualityevidencefromprospective unnecessaryreferralstosecondarycare(seebox2). andretrospectivecohortstudies Box2: Referralcriteriaforspecialistassessmentinadultswithchronic ConsidertestingforCKDusingeGFRcreatinineandACRin kidneydisease(chronic kidney disease) childrenandyoungpeoplewithanyofthefollowingriskfactors: ReferadultswithCKDforspecialistassessment(takingintoaccounttheir wishesandcomorbidities)iftheyhaveanyofthefollowing: Lowbirthweight(≤2500g) A5-yearriskofneedingrenalreplacementtherapyof5%(measured Diabetes usingtheKidneyFailureRiskEquationwhichhasthefourvariables Hypertension age, sex, estimated glomerular filtration rate, andurineACR)3 Cardiacdisease AnACRof≥70mg/mmolunlessthisisknowntobecausedbydiabetes andalreadyappropriatelytreated(seethesectionbelowon Structuralrenaltractdiseaseorrecurrentrenalcalculi pharmacotherapy) Multisystemdiseaseswithpotentialkidneyinvolvement(for AnACRof30mg/mmol(ACRcategoryA3)togetherwithhaematuria example, systemiclupuserythematosus) AsustaineddecreaseineGFRof≥25%andachangeineGFRcategory within12months Familyhistoryofendstagerenaldisease(GFRcategoryG5) orhereditarykidneydisease AsustaineddecreaseineGFRof≥15mL/min/1. 73m 2 peryear Incidentaldetectionofhaematuriaorproteinuria. Hypertensionthatremainspoorlycontrolled(abovethepersons individualtarget)despitetheuseofatleastfourantihypertensive BasedontheexperienceandopinionoftheGuideline medicinesattherapeuticdoses(seealsotheNICEguidelineon Committee(GC) hypertensioninadults4) KnownorsuspectedrareorgeneticcausesofCKD Theguidelinealsoincludesrecommendationsoninvestigationsfor proteinuriaandhaematuriaandtheuseofreagentstrips. Suspectedrenalarterystenosis. Estimatingglomerularfiltrationrate(glomerular filtration rate) Basedonmoderatetohighqualityevidencefromindividualpatient datameta-analysisandprospectiveandretrospectivecohort ThenewguidelinerecommendsthattheestimationofGFR(estimated glomerular filtration rate) studies, anddirectlyapplicablehealtheconomicmodelling shouldnotbeadjustedbyanethnicityfactor(the2014guideline recommendedmultiplyingeGFRby1. 159forpeopleof ThebenefitsofusingtheKidneyFailureRiskEquationoveraneGFR African-CaribbeanorAfricanfamilyorigin, ifcalculatedusingthe threshold(asinthe2014NICEguideline)werenotlargeatan chronic kidney disease-EPIcreatinineequation). TheGuidelineCommitteeagreedthat individuallevel, butthecommitteeagreedthattheywere addinganethnicityadjustmenttoeGFRequationsfordifferent meaningfulatapopulationlevelbecauseofthelargenumberof ethnicitiesmaynotbevalidoraccurate. Categorisationsbasedon peoplewithCKDbeingmanagedinprimarycare. Theyalsoagreed ethnicitylumptogetherpeoplewithadiverserangeoffamily therewereadditionalpotentialbenefitsofusingtheKidneyFailure backgrounds, anddifferencesineGFRacrossethnicitiesarelikely RiskEquation, includingtheabilitytoprovidepeoplewithan toarise, atleastpartly, becauseofdifferencesinaveragemuscle individualriskassessment, whichcouldhelpthemtoproactively massbetweenethnicgroups. However, musclemassalsodiffers managetheirownriskandinformmanagementplansinsecondary frompersontopersonwithinthesameethnicityandsomakingan care. adjustmentbasedonethnicitymaybeinaccurateforsomepeople. Itwasalsoconsideredinappropriatetoextrapolateresearchfindings However, validationoftheriskequationwasonlyinadults, sothe derivedpredominantlyfromAfrican-AmericansintheUStotheUK committeemadeaseparaterecommendationforchildrenandyoung context. Also, theusefulnessofethnicity-basedmodifiersis people. PeopleofAfrican-CaribbeanorAfricanfamilyoriginwere questionableforthemanypeoplefrommixedethnicbackgrounds. under-representedinthevalidationstudyfortheKidneyFailure RiskEquationcomparedwiththeUKaverage, and, althoughthere Therefore, thecommitteenotedthatindividualjudgmentshould wasasizeableproportionofpeopleofAsianfamilyorigin, the beusedwheninterpretingeGFRinpeoplefromUKblack, Asian, locationofthestudysuggeststhatpeopleofeastAsianfamilyorigin andminorityethnicgroups; inadultswithextremesofmusclemass werelikelytobeunder-represented. (suchasbodybuildersorpeoplewhohavehadanamputationor withmusclewastingdisorders)sincereducedmusclemasswilllead GiveadultswithCKDandtheirfamilymembersorcarers(as tooverestimationandincreasedmusclemasstounderestimation appropriate)informationabouttheirfive-yearriskofneeding 2 the bmj BMJ 2021; 374: n1992 doi: 10. 1136/bmj. n1992 PRACTICE renalreplacementtherapy(measuredusingthe4-variableKidney Ifanadult, child, oryoungpersonhasCKD, orisatriskofit, FailureRiskEquation). FollowNICEsguidelineonshared agreethefrequencyofmonitoring(eGFRcreatinineandACR) decisionmakingwhencommunicatingrisk. 5Basedonmoderate withthem(andtheirfamilymembersorcarers, asappropriate), tohighqualityevidencefromindividualpatientdatameta-analysis bearinginmindthatCKDisnotprogressiveinmanypeople. andprospectiveandretrospectivecohortstudies, anddirectly BasedontheexperienceandopinionoftheGC applicablehealtheconomicmodelling Usetable2toguidetheminimumfrequencyofeGFRcreatinine Useeveryday, jargon-freelanguagetocommunicateinformation monitoringbuttailoritaccordingto: onrisk. Iftechnicalandmedicaltermsareused, explainthem clearly. BasedontheexperienceandopinionoftheGC TheunderlyingcauseofCKD Setasideenoughtimeduringtheconsultationtogiveinformation TherateofdeclineineGFRorincreaseinACR(butbeaware onriskassessmentandtoansweranyquestions. Arrangeanother thatCKDprogressionisoftennon-linear) appointmentformorediscussionifthisisneeded. Basedonthe Otherriskfactors, includingheartfailure, Diabetes, and experienceandopinionoftheGC hypertension Documentthediscussiononriskassessmentandanydecisions Changestothepersonstreatment(suchas thepersonmakes. Basedontheexperienceandopinionofthe reninangiotensinaldosteronesystem(RAAS)antagonists, GC NSAIDs, anddiuretics) Monitoringfrequency Intercurrentillness(forexample, acutekidneyinjury) AseGFRdeclines, theriskofkidneydiseaseprogressionand Whetherthepersonhaschosenconservativemanagementof mortalityincreases, andthisriskincreaseswiththerateofeGFR chronic kidney disease. decline. 6AnypersonwitheGFRdeclineidentifiedonroutine Basedonlowtohighqualityevidencefromindividualpatient monitoringshouldbemonitoredmorefrequently. datameta-analysisandprospectivecohortstudies Table2Minimumnumberofmonitoringchecks(eGFRcreatinine)peryearforadults, children, andyoungpeoplewithoratriskofchronickidneydisease (chronic kidney disease) Albumintocreatinineratio(albumin-creatinine ratio)category A1: Normaltomildlyincreased(3 A2: Moderatelyincreased(3-30mg/mmol) A3: Severelyincreased(30mg/mmol) Glomerularfiltrationrate(glomerular filtration rate)category magnesium/mmol) G1: Normalandhigh(≥90mL/min/1. 73m2) 0to1 1 ≥1 G2: Mildreductionrelatedtonormalrangefor 0to1 1 ≥1 ayoungadult(60-89mL/min/1. 73m2) G3a: Mildtomoderatereduction(45-59 1 1 2 milliliters per minute/1. 73m2) G3b: Moderatetoseverereduction(30-44 1to2 2 ≥2 milliliters per minute/1. 73m2) G4: Severereduction(15-29mL/min/1. 73m2) 2 2 3 G5: Kidneyfailure(15mL/min/1. 73m2) 4 ≥4 ≥4 ACRmonitoringshouldbeindividualisedbasedonapersonsindividualcharacteristics, riskofCKDprogression, andwhetherachangeinACRislikelytoleadtoachangeinmanagement. Pharmacotherapy Basedonmoderatetohighqualityevidencefromrandomised controlledtrials, anddirectlyapplicablehealtheconomic TheguidelinenowsupportstheuseofSGLT2inhibitorsforadults analysis withCKD, type2diabetes, andACRof≥30mg/mmolbecausethere wasevidenceofaclinicallymeaningfulreductioninprogression Theguidanceprovidesanalgorithmontheuseofphosphate toendstagekidneydisease, all-causemortality, andhospitalisation binders11andnotestheimportanceoftakingintoaccountpeoples forheartfailurewithSGLT2inhibitorscomparedwithplacebo. 7-9 preferencesaroundchoiceofbinder(forexample, chewableversus Currentstudiesarelookingatwhetherthesecriteriashouldbe non-chewable). Theguidancealsoincludesupdated modifiedforpeoplewithdiabetesandCKD, andanongoingNICE recommendationsonbloodpressurecontrolandappropriateblood TechnologyAppraisalisreviewingtheuseofdapagliflozininpeople pressuretargetsinadults, children, andyoungpeoplewithCKD. withCKDwithorwithoutdiabetes. 10 Implementation ForadultswithCKDandtype2diabetes, offeranSGLT2inhibitor, inadditiontoanARBoranACEinhibitoratanoptimiseddose ItisnotexpectedthatGPsshouldhavetocalculatetheKidney if FailureRiskEquationmanually. Instead, itwouldbebuiltinto laboratorycomputersystems, aspartofhoweGFRandACRresults ACRis30mg/mmoland arereturnedtoGPs.",
    "word_count": 596,
    "char_count": 13901,
    "sentence_count": 69,
    "metadata": {
      "source_file": "184f7326bfd6b935fddfa26044eba920.pdf",
      "extraction_date": "2025-12-31T14:53:18.305289",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "GFR",
        "renal",
        "eGFR"
      ],
      "chunk_index": 0,
      "total_chunks": 2,
      "position": "1/2",
      "content_type": "evidence",
      "content_type_confidence": 9,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "creatinine",
        "magnesium",
        "albumin-creatinine ratio"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 1,
    "text": "withCKDwithorwithoutdiabetes. 10 Implementation ForadultswithCKDandtype2diabetes, offeranSGLT2inhibitor, inadditiontoanARBoranACEinhibitoratanoptimiseddose ItisnotexpectedthatGPsshouldhavetocalculatetheKidney if FailureRiskEquationmanually. Instead, itwouldbebuiltinto laboratorycomputersystems, aspartofhoweGFRandACRresults ACRis30mg/mmoland arereturnedtoGPs. BecausethecalculationrequiresbothaneGFR andACRvalue, itcanbeproducedonlyiftheGPrequestsboththose Theymeetthecriteriainthemarketingauthorisation measurements. Theremaybeanimplementationperiodbeforethe (includingrelevanteGFRthresholds). riskequationresultsareavailabletoallGPs. Untilthen, someGPs the bmj BMJ 2021; 374: n1992 doi: 10. 1136/bmj. n1992 3 PRACTICE mayhavetocontinuetobasereferraldecisionsoneGFRandACR WhatreferralcriteriadoyouusetoreferadultswithCKDforspecialist valuesindependently, asiscurrentlydone, withoutproviding assessment? patientswithaquantitativeassessmentoftheirriskofneedingrenal replacementtherapy. Howpatientswereinvolvedinthecreationofthisarticle TherecommendationforSGLT2inhibitorsmightresultina significantchangeinpractice, sinceitwillmeanthesedrugsare Committeemembersinvolvedinthisguidelineupdateincludedlay prescribedmorewidely, andthiswouldcomewithasubstantial memberswhocontributedtotheformulationoftherecommendations costimpact. Thecommitteenoted, however, thatthiswaslikelyto summarisedhere. representacosteffectiveuseofresources, withthesedrugs providingadditionalbenefitsonrenaloutcomesaswellasthe Contributors: Allauthorscontributedtothedevelopmentoftheguideline; theplanning, drafting, and revisionofthissummary; andapprovalofthefinalversionandtakeresponsibilityforitsaccuracy. We benefitstheyprovidefordiabetesmanagement. thankJoshuaPinkandJanDudleyfortheircommentsonthisarticle. Futureresearch Competinginterests: WedeclaredthefollowinginterestsbasedonNICEspolicyonconflictsofinterests ( interests-policy. pdf). Noneoftheauthorshasanydeclarationsrelevanttothisarticle. Theguideline Inadults, children, andyoungpeoplefromblack, Asian, andother authorsfullstatementscanbeviewedat minorityethnicgroupswithchronickidneydisease(chronic kidney disease)livinginthe UK, whichexistingcalculationsofestimatedglomerularfiltrationrate Funding: YMisanemployeeofNICE. AL, IBandAWreceivednospecificfundingtowritethissummary. (estimated glomerular filtration rate)arethemostaccurate? Inadults, children, andyoungpeoplefromblack, Asian, andother ThemembersoftheGuidelineCommitteewereAnthonyWierzbicki(committeechair), SarahAli (co-optedmember, fromJan2020), ClareAllinson, VirginiaAylett, TaraBashford, NeelBasudev minorityethnicgroupswithCKDlivingintheUK, whatbiomarkersor (co-optedmember, fromJuly2020), IvanBenett, RoyConnell, GrainneConnolly, JanDudley, Andrew factors, otherthanethnicity, improvethediagnosticaccuracyofeGFR Farmer(co-optedmember, fromJan2020toMarch2020), HughGallagher(co-optedmember, from calculations? Jan2020), DeepaKariyawasam, ArifKhwaja, AndrewLewington(CommitteeVice-Chair), FionaLoud, Whatistheaccuracyofthefour-variableKidneyFailureRiskEquation RajibPal, CatherinePogson, NicolaThomas. inadults, children, andyoungpeoplewithCKDfromblack, Asian, and MembersoftheNICEtechnicalteamwereChrisCarmona(untilMay2021); KathrynHopkins(from minorityethnicgroupslivingintheUK? May2021); YolandaMartinez; GabrielRogers(untilJanuary2020); JoshuaPink(fromJanuary2020); Whatistheefficacyandsafetyofdifferentaspirationalhaemoglobin HannahNicholas(untilDecember2019); RuiMartins(fromDecember2019toApril2020), Steph targetsforchildrenandyoungpeoplewithCKDundergoingtreatment Armstrong(fromApril2020). foranaemia? 1 NHSDigital. HealthSurveyforEngland2016: Kidneyandliverdisease. 2017. WhataretheviewsandbeliefsofpeoplewithCKDandtheirfamily tal. nhs. uk/publication/m/e/hse2016-adult-kid-liv. pdf. membersandcarersabouttakingoralphosphatebinders? 2 NationalInstituteforHealthandCareExcellence. Chronickidneydisease: assessmentand management(NICEguidelineNG203). 2021. 3 MajorRW, ShepherdD, MedcalfJF, XuG, GrayLJ, BrunskillNJ. TheKidneyFailureRiskEquation Furtherinformationontheguidance forpredictionofendstagerenaldiseaseinUKprimarycare: Anexternalvalidationandclinical impactprojectioncohortstudy. PLoSMed2019; 16: e1002955. ThisguidancewasdevelopedbyNICEinaccordancewithitsguideline doi: 10. 1371/journal. pmed. 1002955pmid: 31693662 methodology(www. nice. org. uk/media/default/about/what-we-do/our4 NationalInstituteforHealthandCareExcellence. Hypertensioninadults: diagnosisand programmes/developing-nice-guidelines-the-manual. pdf). Aguideline management(NICEguidelineNG136). 2019. committee(GC)wasestablishedbyNICE, whichincorporatedhealthcare 5 NationalInstituteforHealthandCareExcellence. Shareddecisionmaking(NICEguidelineNG197). andalliedhealthcareprofessionals(twoconsultantchemical 2021. pathologists, tworenalphysicians, oneconsultantnephrologist, two 6 CoreshJ, TurinTC, MatsushitaK, etal. Declineinestimatedglomerularfiltrationrateand renalnursespecialists, oneconsultantinmedicinefortheelderly, four subsequentriskofend-stagerenaldiseaseandmortality. JAMA2014; 311: 2518-31. generalpractitioners, onepaediatricrenalnursespecialist, oneconsultant doi: 10. 1001/jama. 2014. 6634pmid: 24892770 paediatricnephrologist, onedietician, onerenalpharmacist, one 7 NeuenBL, OhkumaT, NealB, etal. Effectofcanagliflozinonrenalandcardiovascularoutcomes consultantdiabetologist)andtwolaymembers. acrossdifferentlevelsofalbuminuria: datafromtheCANVASProgram. JAmSocNephrol 2019; 30: 2229-42. doi: 10. 1681/American Society of Nephrology. 2019010064pmid: 31530577 TheGCidentifiedrelevantreviewquestionsandcollectedandappraised 8 PerkovicV, JardineMJ, NealB, etalCREDENCETrialInvestigators. Canagliflozinandrenaloutcomes clinicalandcosteffectivenessevidence. Qualityratingsoftheevidence intype2diabetesandnephropathy. NEnglJMed2019; 380: 2295-306. werebasedonGRADEmethodology(www. gradeworkinggroup. org). These doi: 10. 1056/NEJMoa1811744pmid: 30990260 relatetothequalityoftheavailableevidenceforassessedoutcomesor 9 PollockC, StefánssonB, ReynerD, etal. Albuminuria-loweringeffectofdapagliflozinaloneand themesratherthanthequalityofthestudy. TheGCagreed incombinationwithsaxagliptinandeffectofdapagliflozinandsaxagliptinonglycaemiccontrol recommendationsforclinicalpracticebasedontheavailableevidence inpatientswithtype2diabetesandchronickidneydisease(DELIGHT): arandomised, double-blind, or, whenevidencewasnotfound, basedontheirexperienceandopinion placebo-controlledtrial. LancetDiabetesEndocrinol2019; 7: 429-41. usinginformalconsensusmethods. doi: 10. 1016/S2213-8587(19)30086-5pmid: 30992195 Thescopeandthedraftoftheguidelinewentthrougharigorousreviewing 10 NationalInstituteforHealthandCareExcellence. Dapagliflozinfortreatingchronickidneydisease. process, inwhichstakeholderorganisationswereinvitedtocomment; theGCtookallcommentsintoconsiderationwhenproducingthefinal 11 NationalInstituteforHealthandCareExcellence. NG203Chronickidneydiseasestages4and versionoftheguideline. Theguidelineisavailableat 5: phosphatebinders. 2021. NICEwillconductregularreviewsafterpublicationoftheguidance, to determinewhethertheevidencebasehasprogressedsignificantlyenough toalterthecurrentguidelinerecommendationsandrequireanupdate. Guidelinesintopractice Whenwouldyouconsideradjustingestimatedglomerularfiltration rate(estimated glomerular filtration rate)inadultsatriskofchronickidneydisease(chronic kidney disease)? 4 the bmj BMJ 2021; 374: n1992 doi: 10. 1136/bmj. n1992",
    "word_count": 350,
    "char_count": 7466,
    "sentence_count": 85,
    "metadata": {
      "source_file": "184f7326bfd6b935fddfa26044eba920.pdf",
      "extraction_date": "2025-12-31T14:53:18.305289",
      "document_type": "medical_guideline",
      "language": "en",
      "year": "2021",
      "keywords": [
        "chronic kidney disease",
        "CKD",
        "GFR",
        "renal",
        "eGFR"
      ],
      "chunk_index": 1,
      "total_chunks": 2,
      "position": "2/2",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "albuminuria"
      ],
      "entity_count": 3
    }
  }
]